医药和生技产业资产收购交易：2019-2026

本报告对全球生命科学产业的资产收购交易进行了全面分析。报告专为业务拓展、授权和企业策略专业人士设计，深入剖析了企业如何建立资产收购交易以及如何就相关财务条款进行谈判。

这份经过全面修订和更新的报告分析了自2019年以来公布的资产收购协议，揭示了医药和生物技术公司如何透过策略交易获取业务资产、产品资产、特许权使用费权益和技术资产。

每项交易记录均包含可用的财务条款，并提供指向详细线上交易记录和已向监管机构提交的合约文件的连结。结合交易数据、财务基准和合约文件，用户可以评估类似交易并制定更有效的资产收购策略。

主要优势

• 显着缩短研究时间

无需再搜寻多份新闻稿、资料库和监管文件，即可存取统一的资产收购交易资料库。

• 资产收购交易结构基准分析

您可以了解製药和生技公司如何依业务部门、产品、技术和特许权使用费收入流建立资产收购协议。

• 财务条款分析

您可以查看公开的财务资讯（交易总额、预付款、里程碑付款、特许权使用费协议等），以对标交易价值和结构。

• 存取实际合约文件

您可以查看已向美国证券交易委员会 (SEC) 提交的资产收购协议（如有公开文件），以更深入地了解实际交易中的合约条款。

• 辨识最活跃的资产收购公司

我们辨识出资产收购领域最活跃的公司，并分析其策略交易活动。

• 追踪产业趋势

我们分析了自 2019 年以来，依公司、治疗领域和技术类型划分的资产收购交易趋势。

目录

摘要整理

第一章：引言

第二章：资产收购交易趋势

• 收购资产类型
• 自 2019 年以来的资产收购交易趋势
  • 依年份
  • 依研发阶段
  • 依行业板块
  • 依治疗领域
  • 依技术分类
  • 最活跃的公司
• 进行资产收购交易的原因
  • 业务资产
  • 产品资产
  • 特许权使用费资产
  • 技术资产
• 资产收购交易的未来

第三章：资产收购交易架构概论

• 资产收购交易结构

第四章：主要资产收购交易

• 主要资产收购交易：以价值分类

第五章：最活跃的25家资产收购公司

• 最活跃的25家资产收购公司公司

第六章：合作协议目录：包含协议

• 合作协议：包含协议
• 协定目录
• 协议目录 - 依公司（A-Z）分类
• 协议目录 - 依治疗领域分类
• 协定目录 - 依技术分类
• 关于 Biopharma Research Ltd
• 当前合作关係
• 当前协议
• 近期合作报告标题

Benchmark Asset Acquisition Strategies Across the Global Biopharma Industry

Free report sample

The Asset Purchase Deals in Pharmaceuticals and Biotechnology 2019-2026 report provides a comprehensive analysis of asset acquisition transactions across the global life sciences industry. Designed for business development, licensing, and corporate strategy professionals, the report delivers detailed insight into how companies structure asset purchase deals and negotiate the financial terms behind these transactions.

Fully revised and updated, the report analyzes asset purchase agreements announced since 2019, providing a detailed view of how pharmaceutical and biotechnology companies acquire business assets, product assets, royalty interests, and technology assets through strategic transactions.

Each deal record includes financial terms where available and links to detailed online deal records and contract documents filed with regulators when publicly disclosed. This combination of deal data, financial benchmarking, and contract access enables users to evaluate comparable transactions and structure more effective asset acquisition strategies.

Key Benefits

• Save Significant Research Time

Access a consolidated database of asset purchase deals rather than searching multiple press releases, databases, and regulatory filings.

• Benchmark Asset Purchase Deal Structures

Understand how pharmaceutical and biotechnology companies structure asset acquisition agreements across business units, products, technologies, and royalty streams.

• Analyze Financial Terms with Confidence

Review disclosed financial information-including headline deal values, upfront payments, milestones, and royalty arrangements-to benchmark transaction values and structures.

• Access Real Contract Documents

Where available, explore SEC-filed asset purchase agreements, providing deeper insight into the contractual provisions behind real-world deals.

• Identify the Most Active Asset Acquisition Dealmakers

Discover which companies are most active in asset acquisitions and analyze their strategic transaction activity.

• Track Industry Trends

Analyze asset purchase dealmaking trends since 2019 across companies, therapeutic areas, and technology types.

What's Included in the Report

Analysis of asset purchase dealmaking trends since 2019

Overview of asset acquisition deal structures and transaction models

Review of the leading asset purchase deals by headline value

Profiles of the top 25 most active asset purchase dealmakers

Detailed analysis of deals organized by company, therapeutic area, technology type, and industry sector

A comprehensive deal directory covering asset purchase transactions announced since 2019

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual asset purchase contracts, the report enables users to evaluate key transaction provisions such as:

• Asset ownership and transfer rights
• Financial payment structures and transaction values
• Intellectual property rights and technology transfer provisions
• Commercialization and development obligations
• Royalty structures and ongoing financial participation
• Contract duration and termination provisions
• Access to real agreements provides insight into the detailed terms negotiated between companies-information rarely disclosed in press releases or traditional deal databases.
• Why This Report Matters
• Asset purchase transactions are an important strategic tool in the pharmaceutical and biotechnology industries, enabling companies to acquire technologies, products, and royalty streams to strengthen their pipelines and portfolios.
• By combining comprehensive deal data, financial benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, structure stronger asset purchase agreements, and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals since 2019
  • 2.3.1. Asset purchase dealmaking by year
  • 2.3.2. Asset purchase dealmaking by phase of development
  • 2.3.3. Asset purchase dealmaking by industry sector
  • 2.3.4. Asset purchase dealmaking by therapy area
  • 2.3.5. Asset purchase dealmaking by technology type
  • 2.3.6. Asset purchase dealmaking by most active company
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements
• Figure 3: Asset purchase deals signed at each phase of development
• Figure 4: Asset purchase deals by industry sector
• Figure 5: Asset purchase deals by therapy area
• Figure 6: Asset purchase deals by technology type
• Figure 7: Top 25 most active asset purchase dealmakers
• Figure 8: Top asset purchase deals by value
• Figure 9: Most active asset purchase dealmakers